Abstract
Introduction: Obesity is a public health condition that results in adverse health impacts and, together with overweight, is one of the main risk factors for the development of type 2 diabetes mellitus. Semaglutide , an analogue of glucagon-like peptide 1 (GLP-1) , has emerged as a promising therapeutic option in the management of obesity, since it can be prescribed for both glycemic control and weight reduction.Methodology: An integrative review was carried out in the databases indexed by the Virtual Health Library (VHL), using as inclusion criteria primary articles published in 2024 in English, with 8 works selected. Results and discussion: Semaglutide has been shown to be an effective pharmacological treatment for patients with type 2 Diabetes Mellitus. Both its weekly subcutaneous and daily oral presentation were able to reduce the average weight and BMI of patients with a variation between 3% and 6% in 3 to 12 months, with the reduction being proportional to the dosage. However, adverse effects were frequent in patients, mostly mild and involving nausea, diarrhea, and constipation, sometimes sufficient to impair adherence. Conclusion : Semaglutide is a safe and effective pharmacological option for the treatment of obesity and overweight in type 2 diabetics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
